Replimune Group (NASDAQ:REPL) Rating Increased to Overweight at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report issued on Friday, MarketBeat.com reports.

Other research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a report on Friday, April 10th. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Stock Up 0.7%

REPL stock traded up $0.08 during mid-day trading on Friday, reaching $11.21. The company had a trading volume of 3,671,419 shares, compared to its average volume of 4,650,596. The firm has a fifty day simple moving average of $6.05 and a 200 day simple moving average of $7.27. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The company has a market capitalization of $925.73 million, a price-to-earnings ratio of -3.21 and a beta of 0.91. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $13.24.

Insider Activity at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. International Assets Investment Management LLC bought a new stake in Replimune Group during the fourth quarter worth $29,000. Russell Investments Group Ltd. increased its holdings in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the last quarter. CWM LLC boosted its stake in Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC increased its stake in shares of Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after purchasing an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Replimune Group by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after purchasing an additional 6,873 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.